FINWIRES · TerminalLIVE
FINWIRES

Diamondback Energy Can Pursue More Growth Opportunities if Elevated Oil Macro Persists, RBC Says

By

-- Diamondback Energy's (FANG) decision to pursue growth was not surprising, and there is appetite and capability for more if the elevated oil macro persists, RBC Capital Markets said Tuesday in a note.

Management moved away from the "stop light" analogy and has the inventory duration and quality to support growth, the firm said. This is a value enhancing decision that increases the free cash flow profile over the next few years, the brokerage said.

RBC models 988,000 barrels of oil equivalent per day, ahead of the new 2026 guidance of over 972,000 barrels of oil equivalent per day, while remaining in line with the $3.9 billion capital plan, according to the note.

The new plan is more opportunistic to drive shareholder value and sidelines variable dividends, RBC said.

The company will likely pay down about $1.3 billion of notes in early Q2, the firm said. Management's longer-term $10 billion net debt target has also been pulled forward and will likely be achieved in months. It may also target some of the pre-2030 bond maturities, the brokerage added.

RBC maintained an outperform rating on Diamondback Energy with a price target of $240.

Shares of Diamondback Energy were down 5.7% in Wednesday trading.

Price: $194.55, Change: $-11.64, Percent Change: -5.64%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL